|Bid||0.00 x 1200|
|Ask||10.33 x 1100|
|Day's Range||6.33 - 6.37|
|52 Week Range||5.42 - 16.90|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The big shareholder groups in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have power over the company. Large companies...
After its acquisition of Warp Drive Bio last year, this Redwood City biotech company took its cancer-fighting trek into the "undruggable" universe.
The average return on U.S. IPOs in the second quarter was 30 percent, a mark hit or exceeded by 11 of the Bay Area's 23 new public companies so far this year.
Looking deeper into a target of a CRISPR deal, a fundraising for more-targeted approach to mental health therapies and more in our Health Care Digest.